P453: Therapeutic levels of digoxin could be different in elderly patientsObjective: To measure changes in the practice of palliative sedation during agony in hospitalised elderly patients before and after the implementation of a palliative sedation protocol. Material and methods: A retrospective before-...
Both patients experienced these symptoms while receiving digoxin.Both patients had digoxin blood levels in the therapeutic range (1.7 and 1.0 ng/ml, respectively). Therapeutic levels are 0.5 to 2.0 ng/ml. After discontinuing digoxin, the first patient noted that the shimmering light symptoms ...
The clinical role of digoxin for the treatment of congestive heart failure has recently been questioned, although it still has a role in some patients. Many drugs can interact with digoxin and care should be taken when these drugs are used in conjunction with digoxin therapy. Treatment is ...
DO WE NEED A THREE‐COMPARTMENT MODEL FOR THE PREDICTION OF DIGOXIN BLOOD LEVELS ON MULTIPLE DOSING? First page of article L Balant,CA Hunt - 《Journal of Clinical Pharmacy & Therapeutics》 被引量: 2发表: 2010年 The Effect of Everyday Exercise on Steady State Digoxin Concentrations The purpos...
method of Dasgupta et al.CONCLUSION There are certain increased concentrations of DLIS in sera of the patients with cardiac insufficiency,suggesting that digoxin levels measured by immunoassay method must be interpreted carefully in these patients after treatment with digoxin or other digitalis preparations...
may require regular monitoring of drug levels examples include: warfarin lithium digoxin phenytoin gentamicin amphotericin 5-fluoro-urocil zidovudine Therapeutic drug monitoring therapeutic window (TW) is the range of drug concentrations in which a drug is effective TW concept is refle...
Hence, there is small variation between therapeutic and toxic dosage of digoxin. Abundant conventional methods have been introduced for digoxin monitoring such Liquid chromatography (LC), LC–MS, HPLC. However, they suffer expensive equipment, long lasting procedure and high limit of detection. Hence...
pharmacogenomics and the application of biomarkers in therapeutic drug monitoring. This reference also discusses the limitations of current commercially available immunoassays for therapeutic monitoring. It presents new and sophisticated techniques used for proper determination of blood levels and the clinical ...
Thus, our results indicated that miR-338-3p can serve as a possible novel biomarker for the prognosis of IDD. Based on several computational tools, SIRT6 was determined to be the direct target of miR-338-3p. Furthermore, our results revealed that the expression levels of SIRT6 were ...
In contrast, HIF-1α mRNA levels increased during treatment. Of note, the in vitro doses used were much higher than circulating therapeutic doses of digoxin and would, therefore, be expected to induce severe toxicity (Lopez-Lazaro, 2009). Also, species-related differences in cardiac glycoside ...